This is a summary of the European public assessment report (EPAR) for Praxbind. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Praxbind. For practical information about using Praxbind, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: - for emergency surgery/urgent procedures; - in life-threatening or uncontrolled bleeding.
Therapeutic Area (MeSH)
ATC Code
V03AB
ATC Item
解毒剂
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| idarucizumab | N/A | 依达赛珠单抗 |
EMA Name
Praxbind
Medicine Name
Praxbind
Aliases
N/A